Vivos Inc Summarizes Progress in its Animal Therapy Division
The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary adoption nationwide. In recent months, the Company has seen a sharp rise…
Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals. The two companies have…
New Radiation Therapy in New Jersey is Showing Promise in Treating Cancer in Pets
By Stephanie Stahl, Casey Kuhn Updated on: October 27, 2025 / 8:39 PM EDT / CBS Philadelphia A new type of radiation therapy is showing promise in treating cancer in…
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated…
Vista Veterinary Hospital has been awarded one of America’s Best Animal Hospitals 2025
The ranking of America’s Best Animal Hospitals recognizes the top 500 animal hospitals in the United States based on quality of care provided. To identify the top 500 animal hospitals, we…
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024
Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in veterinary cancer care, and expanding its network of certified…
